Allogene Therapeutics, Inc. SEC filings ALLO
Allogene Therapeutics, Inc. has 585 filings in SEC EDGAR's recent list, going back to Apr 19, 2018. Its latest annual report, Form ARS, was filed on Apr 30, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 12, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Nov 5, 2026 (results of operations). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| DEFA14A | Additional proxy material | May 28, 2026 | — |
| DEFA14A | Additional proxy material | May 21, 2026 | — |
| DEFA14A | Additional proxy material | Apr 30, 2026 | — |
| DEF 14A | Proxy statement | Apr 30, 2026 | Jun 18, 2026 |
| PRE 14A | Preliminary proxy statement | Apr 20, 2026 | Apr 20, 2026 |
| DEFA14A | Additional proxy material | Apr 30, 2025 | — |
| DEF 14A | Proxy statement | Apr 30, 2025 | Jun 18, 2025 |
| DEFA14A | Additional proxy material | Apr 23, 2024 | — |
| DEF 14A | Proxy statement | Apr 23, 2024 | Jun 5, 2024 |
| DEFA14A | Additional proxy material | Apr 24, 2023 | — |
| DEF 14A | Proxy statement | Apr 24, 2023 | — |
| DEFA14A | Additional proxy material | Apr 26, 2022 | — |
| DEF 14A | Proxy statement | Apr 26, 2022 | Jun 15, 2022 |
| PRE 14A | Preliminary proxy statement | Apr 14, 2022 | Jun 15, 2022 |
| DEFA14A | Additional proxy material | Apr 22, 2021 | — |
| DEF 14A | Proxy statement | Apr 22, 2021 | Jun 10, 2021 |
| DEFA14A | Additional proxy material | Apr 23, 2020 | — |
| DEF 14A | Proxy statement | Apr 23, 2020 | Dec 31, 2019 |
| DEFA14A | Additional proxy material | Apr 24, 2019 | — |
| DEF 14A | Proxy statement | Apr 24, 2019 | Jun 6, 2019 |
Showing 20 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- ALLO (Nasdaq)
- Fiscal year ends
- December 31
- Headquarters
- South San Francisco, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1737287
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.